Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.

Actual average ($3,959.05 versus $4,256.28, respectively; P = 0.55) and log-transformed average hospital costs ($3,376.57 versus $3,588.68; P = 0.63) were lower in the oritavancin cohort compared to cohort B, but did not reach statistical significance.

also in 111,027 other papers